BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 27781490)

  • 1. Dabrafenib in BRAFV600-mutated anaplastic pleomorphic xanthoastrocytoma.
    Brown NF; Carter T; Mulholland P
    CNS Oncol; 2017 Jan; 6(1):5-9. PubMed ID: 27781490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using personalized medicine in gliomas: a genomic approach to diagnosis and overcoming treatment resistance in a case with pleomorphic xanthoastrocytoma.
    Piña Y; Fusco MJ; Macaulay RJ; Walko CM; Peguero E; Evernden BR; Smalley KS; Forsyth P
    J Neurol; 2020 Mar; 267(3):783-790. PubMed ID: 31748891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges of targeting
    Smith-Cohn M; Davidson C; Colman H; Cohen AL
    CNS Oncol; 2019 Dec; 8(4):CNS48. PubMed ID: 31818130
    [No Abstract]   [Full Text] [Related]  

  • 4. Primary Meningeal Pleomorphic Xanthoastrocytoma With Anaplastic Features: A Report of 2 Cases, One With BRAF(V600E) Mutation and Clinical Response to the BRAF Inhibitor Dabrafenib.
    Usubalieva A; Pierson CR; Kavran CA; Huntoon K; Kryvenko ON; Mayer TG; Zhao W; Rock J; Ammirati M; Puduvalli VK; Lehman NL
    J Neuropathol Exp Neurol; 2015 Oct; 74(10):960-9. PubMed ID: 26352988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to BRAF/MEK Inhibition After Progression With BRAF Inhibition in a Patient With Anaplastic Pleomorphic Xanthoastrocytoma.
    Hussain F; Horbinski CM; Chmura SJ; Yamini B; Lukas RV
    Neurologist; 2018 Sep; 23(5):163-166. PubMed ID: 30169370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status.
    Thompson EM; Landi D; Ashley D; Keir ST; Bigner D
    J Neurooncol; 2018 Nov; 140(2):261-268. PubMed ID: 30120661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful Treatment of a Progressive BRAF V600E-Mutated Anaplastic Pleomorphic Xanthoastrocytoma With Vemurafenib Monotherapy.
    Lee EQ; Ruland S; LeBoeuf NR; Wen PY; Santagata S
    J Clin Oncol; 2016 Apr; 34(10):e87-9. PubMed ID: 25092772
    [No Abstract]   [Full Text] [Related]  

  • 8. Combined pleomorphic xanthoastrocytoma-ganglioglioma with BRAF V600E mutation: case report.
    Cicuendez M; Martinez-Saez E; Martinez-Ricarte F; Asanza EC; Sahuquillo J
    J Neurosurg Pediatr; 2016 Jul; 18(1):53-7. PubMed ID: 27015517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF V600E, TERT, and IDH2 Mutations in Pleomorphic Xanthoastrocytoma: Observations from a Large Case-Series Study.
    Ma C; Feng R; Chen H; Hameed NUF; Aibaidula A; Song Y; Wu J
    World Neurosurg; 2018 Dec; 120():e1225-e1233. PubMed ID: 30240866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of a Promoter Mutation in TERT in Malignant Transformation of Pleomorphic Xanthoastrocytoma.
    Hosono J; Nitta M; Masui K; Maruyama T; Komori T; Yokoo H; Saito T; Muragaki Y; Kawamata T
    World Neurosurg; 2019 Jun; 126():624-630. PubMed ID: 30599247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF mutation and anaplasia may be predictive factors of progression-free survival in adult pleomorphic xanthoastrocytoma.
    Tabouret E; Bequet C; Denicolaï E; Barrié M; Nanni I; Metellus P; Dufour H; Chinot O; Figarella-Branger D
    Eur J Surg Oncol; 2015 Dec; 41(12):1685-90. PubMed ID: 26454767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dabrafenib and trametinib in BRAFV600E mutated glioma.
    Brown NF; Carter T; Kitchen N; Mulholland P
    CNS Oncol; 2017 Oct; 6(4):291-296. PubMed ID: 28984141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained Response to Targeted Therapy in a Patient With Disseminated Anaplastic Pleomorphic Xanthoastrocytoma.
    Amayiri N; Swaidan M; Al-Hussaini M; Halalsheh H; Al-Nassan A; Musharbash A; Tabori U; Hawkins C; Bouffet E
    J Pediatr Hematol Oncol; 2018 Aug; 40(6):478-482. PubMed ID: 29200156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review.
    Andrews LJ; Thornton ZA; Saincher SS; Yao IY; Dawson S; McGuinness LA; Jones HE; Jefferies S; Short SC; Cheng HY; McAleenan A; Higgins JPT; Kurian KM
    Neuro Oncol; 2022 Apr; 24(4):528-540. PubMed ID: 34718782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pleomorphic xanthoastrocytoma, anaplastic pleomorphic xanthoastrocytoma, and epithelioid glioblastoma: Case series with clinical characteristics, molecular features and progression relationship.
    Lin Z; Yang R; Zheng H; Li Z; Yi G; Wu Q; Yang C; Huang G
    Clin Neurol Neurosurg; 2022 Oct; 221():107379. PubMed ID: 35932588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRAF inhibition with concomitant tumor treating fields for a multiply progressive pleomorphic xanthoastrocytoma.
    Lukas RV; Merrell RT
    CNS Oncol; 2018 Apr; 7(2):CNS10. PubMed ID: 29708404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dabrafenib in BRAFV600E mutant pilocytic astrocytoma in a pediatric patient.
    Mustansir F; Mushtaq N; Darbar A
    Childs Nerv Syst; 2020 Jan; 36(1):203-207. PubMed ID: 31418082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF-Mutated Pleomorphic Xanthoastrocytoma of the Spinal Cord with Eventual Anaplastic Transformation.
    Hong CS; Wang JL; Dornbos D; Joehlin-Price A; Elder JB
    World Neurosurg; 2017 Feb; 98():871.e9-871.e15. PubMed ID: 27956254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dabrafenib for Pilocytic Astrocytoma With
    Tanaka R; Mrachek K; Arocho-Quinones E; Carlberg VM; Smith C; Kurzrock R; Deshmukh T
    JCO Precis Oncol; 2024 May; 8():e2400055. PubMed ID: 38781546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebellar Pleomorphic Xanthoastrocytoma with BRAF V600E Mutation.
    Kim SH; Hwang K; Lee KS; Choe G; Kim CY
    World Neurosurg; 2020 Jul; 139():577-581. PubMed ID: 32348888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.